{
    "clinical_study": {
        "@rank": "100795", 
        "acronym": "GREAT", 
        "arm_group": [
            {
                "arm_group_label": "Liraglutide", 
                "arm_group_type": "Experimental", 
                "description": "Once a day 1,8 mg subcutaneous injection for 16 weeks"
            }, 
            {
                "arm_group_label": "Liraglutide placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once a day 1,8 mg subcutaneous injection for 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Metabolic disturbances, obesity and life-shortening cardiovascular morbidity are major\n      clinical problems among antipsychotic-treated patients. Especially two of the most\n      efficacious antipsychotics, clozapine and olanzapine, cause weight gain and metabolic\n      disturbances and can rarely be replaced by other drugs due to the effectiveness of the\n      compounds. Glucagon-like peptide 1 (GLP-1) has improved glycemic control among patients with\n      type 2 diabetes. The study will investigate whether the beneficial effects of GLP-1\n      analogues on glycemic control in type 2 diabetic patients, can be extended to a population\n      of non-diabetic, dysglycemic psychiatric patients, receiving antipsychotic medical\n      treatment."
        }, 
        "brief_title": "Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Impaired Glucose Tolerance Associated With Drugs", 
        "condition_browse": {
            "mesh_term": "Glucose Intolerance"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed oral and written consent\n\n          -  Diagnosed with schizophrenia, schizotypal disorder or paranoid psychosis according to\n             the criteria of ICD10 (International Classification of Diseases, World Health\n             Organization) or the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders,\n             Fourth Edition, the American Psychiatric Association)\n\n          -  and on stable antipsychotic treatment with either clozapine or olanzapine for at\n             least 6 months (without dose change for at least 30 days)\n\n          -  Stable co-medications for at least 30 days.\n\n          -  Age \u226518 years and \u226465 years\n\n          -  Stable weight (defined as less than 5% change in weight over the last 3 month before\n             inclusion)\n\n          -  BMI \u226527 kg/m2\n\n          -  Dysglycaemia (IFG, i.e. fasting plasma glucose level from 6.1 mmol/L to 6.9 mmol/L or\n             IGT, i.e. two-hour glucose levels of 7.8 to 11.0 mmol on the 75-g oral glucose\n             tolerance test and a fasting plasma glucose of less than 7.0 mmol/L).\n\n        Exclusion Criteria:\n\n          -  Compulsory treatment\n\n          -  Females of child bearing potential who are pregnant, breast-feeding or have intention\n             of becoming pregnant or are not using adequate contraceptive measures\n\n          -  Subjects treated with corticosteroids or other hormone therapy (except estrogens)\n\n          -  Any active substance abuse or dependence for the past 6 months (except for nicotine)\n\n          -  Impaired hepatic function (liver transaminases >2 times upper normal limit)\n\n          -  Impaired renal function (se-creatinine >150 \u03bcM and/or macroalbuminuria)\n\n          -  Impaired pancreatic function (acute or chronic pancreatitis and/or amylase >2 times\n             upper normal limit)\n\n          -  Cardiac problems defined as decompensated heart failure (NYHA class III or IV),\n             unstable angina pectoris and/or myocardial infarction within the last 12 months\n\n          -  Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood\n             pressure >100 mmHg)\n\n          -  Any condition that the investigator feels would interfere with trial participation\n\n          -  Receiving any investigational drug within the last 3 months\n\n          -  Use of weight-lowering pharmacotherapy within the preceding 3 month\n\n          -  Type 1 or 2 diabetes with HbA1c > 6.5%"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845259", 
            "org_study_id": "GLP-1 antipsychotics", 
            "secondary_id": [
                "2013-000121-31", 
                "U1111-1128-3404"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide", 
                "description": "Once a day 1,8 mg subcutaneous injection for 16 weeks", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Victoza", 
                    "GLP-1 agonist"
                ]
            }, 
            {
                "arm_group_label": "Liraglutide placebo", 
                "description": "Once a day 1,8 mg subcutaneous injection for 16 weeks", 
                "intervention_name": "Liraglutide Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antipsychotic Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "July 5, 2013", 
        "link": {
            "description": "Web page about the study for patients and caregivers", 
            "url": "http://psyktreat.sharepoint.com"
        }, 
        "location": {
            "contact": {
                "email": "a.fink-jensen@dadlnet.dk", 
                "last_name": "Anders Fink-Jensen, MD, DMsci", 
                "phone": "+45 22755843"
            }, 
            "contact_backup": {
                "email": "dr.rask@gmail.com", 
                "last_name": "Julie F Rask Larsen, MD", 
                "phone": "+45 22977757"
            }, 
            "facility": {
                "address": {
                    "city": "Copenhagen", 
                    "country": "Denmark", 
                    "state": "K\u00f8benhavn \u00d8", 
                    "zip": "2100"
                }, 
                "name": "Psychiatric Centre Rigshospitalet"
            }, 
            "investigator": [
                {
                    "last_name": "Anders Fink-Jensen, MD, DMSci", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Julie F Rask Larsen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "2", 
        "official_title": "Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial", 
        "other_outcome": [
            {
                "description": "AUDIT (Alcohol Use Disorder Identification Test)", 
                "measure": "Alcohol use", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks from baseline - 16 weeks"
            }, 
            {
                "measure": "Changes i dietary and exercise records", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks from baseline - 16 weeks"
            }
        ], 
        "overall_contact": {
            "email": "a.fink-jensen@dadlnet.dk", 
            "last_name": "Anders Fink-Jensen, MD, DMSci", 
            "phone": "+45 22755843"
        }, 
        "overall_contact_backup": {
            "email": "dr.rask@gmail.com", 
            "last_name": "Julie F Rask Larsen, MD", 
            "phone": "+45 22977757"
        }, 
        "overall_official": [
            {
                "affiliation": "Psychiatric Centre Rigshospitalet", 
                "last_name": "Anders Fink-Jensen, MD, DMSci", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Diabetes Research Division, Gentofte", 
                "last_name": "Tina Vilsb\u00f8ll, MD, DMSci", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Denmark: Danish Health and Medicines Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in Glucose tolerance (measured by area under the curve (AUC) for plasma glucose (PG) excursion following a 4-hour 75 g Oral Glucose Tolerance Test (OGTT))", 
            "measure": "Glucose tolerance", 
            "safety_issue": "No", 
            "time_frame": "Baseline - 16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845259"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Psychiatric Centre Rigshospitalet", 
            "investigator_full_name": "Anders Fink-Jensen, MD, DMSci", 
            "investigator_title": "Professor, MD, DMSci", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change in dysglycaemia (Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT), combined IFG/IGT or diabetes)", 
                "measure": "Dysglycaemia", 
                "safety_issue": "No", 
                "time_frame": "Baseline - 16 weeks"
            }, 
            {
                "measure": "Body weight", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks from baseline - 16 weeks"
            }, 
            {
                "description": "Evaluated by Homeostatic Model of Assessment (HOMA)", 
                "measure": "Secretion of incretin hormons, insulin sensitivity and beta cell function", 
                "safety_issue": "No", 
                "time_frame": "Baseline - 16 weeks"
            }, 
            {
                "description": "Dual energy x-ray absorptiometry (DEXA)-scan", 
                "measure": "Body composition", 
                "safety_issue": "No", 
                "time_frame": "Baseline - 16 weeks"
            }, 
            {
                "description": "Blood sample", 
                "measure": "Lipid profile and liver function", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks from baseline - 16 weeks"
            }, 
            {
                "description": "Schizophrenia Quality of Life Scale (SQLS), Clinical Global Impression-Severity (CGI-S), Clinical Global Impression-Improvement (CGI-I), Global Assessment of Function (GAF)", 
                "measure": "Psychopathology", 
                "safety_issue": "No", 
                "time_frame": "Baseline - 16 weeks"
            }, 
            {
                "measure": "Waist circumference", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks from baseline - 16 weeks"
            }, 
            {
                "measure": "Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks from baseline - 16 weeks"
            }
        ], 
        "source": "Psychiatric Centre Rigshospitalet", 
        "sponsors": {
            "collaborator": {
                "agency": "University Hospital, Gentofte, Copenhagen", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Psychiatric Centre Rigshospitalet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}